Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application

References

• Tilly W, Wust P, Rau B, Harder C, Gellermann J, Schlag P, et al. Temperature data and specific absorption rates in pelvic tumours: Predictive factors and correlations. Int J Hyperthermia 2001;17:172–88
   PubMed Web of Science ®Google Scholar
• Song CW, Park JH, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005;21:761–7
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arangeli G, Dahl O, Mella O, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet 1995;345:540–3
   PubMed Web of Science ®Google Scholar
• van der Zee, Gonzalez Gonzales D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;344(9210):1119–25
   Google Scholar
• Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731–44
   PubMed Web of Science ®Google Scholar
• Jones EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, et al. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079–85
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11:561–70
   PubMed Web of Science ®Google Scholar
• Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J, et al. Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 2011;187:605–10
   PubMed Web of Science ®Google Scholar
• Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33–56
   PubMed Web of Science ®Google Scholar
• Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int Radiat Biol Relat Stud Phys Chem Med 1971;19:467–77
   PubMed Web of Science ®Google Scholar
• Dewey WC, Thrall DE, Gillette EL. Hyperthermia and radiation – a selective thermal effect on chronically hypoxic tumor cells in vivo. Int J Radiat Oncol Biol Phys 1977;2:99–103
   PubMed Web of Science ®Google Scholar
• Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994;10:457–83
   PubMed Web of Science ®Google Scholar
• Thorary-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia 2014;30:531–9
   PubMed Web of Science ®Google Scholar
• Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005;280:33097–100
   PubMed Web of Science ®Google Scholar
• Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564–72
   PubMed Web of Science ®Google Scholar
• Slimen IB, Najar T, Ghram A, Dabbebi A, Mrad MB Abdrabbah M. Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review. Int J Hyperthermia 2014;30:513–23
   PubMed Web of Science ®Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3:487–97
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Lee CT, Ashcraft KA. The future of biology in driving the field of hyperthermia. Int J Hyperthermia 2015. (in press)
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–74
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for mestastatic breast cancer the overexpresses HER2. N Engl J Med 2001;344:783–92
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692–703
   PubMed Web of Science ®Google Scholar
• Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Eng J Med 2002;347:481–7
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stroma tumors. Science 2003;299:708–10
   PubMed Web of Science ®Google Scholar
• Borg C, Terme M, Taieb J, Ménard C, Flament C, Robert C, Maruyama K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004;114:379–88
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kroemer G. Anticancer effects of imatinib via immunostimulation. Nat Med 2011;17:1050–1
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499–510
   PubMed Web of Science ®Google Scholar
• Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013;31:1592–602
   PubMed Web of Science ®Google Scholar
• Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008;44:2546–54
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization mode of action and clinical relevance. Int J Radiat Biol 2001;77:399–408
   PubMed Web of Science ®Google Scholar
• Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia 2012;28:509–17
   PubMed Web of Science ®Google Scholar
• Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, et al. Mild hyperthermia inhibits homologous recombination, induces BRACA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011;108:9851–6
   PubMed Web of Science ®Google Scholar
• Powell SN, Kachnic LA. Homologous recombination is heating up and ready for therapy. Proc Natl Acad Sci USA 2011;108:9731–2
   PubMed Web of Science ®Google Scholar
• Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, et al. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene 2014;2:33:4803–12
   Google Scholar
• Xia B1, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006;23:719–29
   Web of Science ®Google Scholar
• Ma YX, Fan S, Xiong J, Yuan R, Meng Q, Gao M, et al. Role of BRCA1 in heat shock response. Oncogene 2003;22:10–27
   PubMed Web of Science ®Google Scholar
• Blay JY, Blomquist C, Bonvalet S, Boukovinas I, Casali PG, De Alava E, et al. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol 2012;23(Suppl 7):vii92–9
   PubMedGoogle Scholar
• D’Incalci M, Galmarini CM. A review of trabectedin (ET-743): A unique mechanism of action. Mol Cancer Ther 2010;9:2157–63
   PubMed Web of Science ®Google Scholar
• Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66:8155–62
   PubMed Web of Science ®Google Scholar
• Italiano A, Laurand A, Laroch A, Casali P, Sanfilippo R, Le Cesne A, et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer 2011;117:3445–56
   PubMed Web of Science ®Google Scholar
• Laroche-Clary A, Chaire V, Le Morvan V, Neuville A, Bertucci F, Salas S, et al. BRCA1 haplotype and clinical benefit of trabectedin in soft tissue sarcoma patients. Br J Cancer 2015;112:688–92
   PubMed Web of Science ®Google Scholar
• Schoeffski P, Taron M, Jimeno J, Grosso F, Sanfilippo R, Casali PG, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. Eur J Cancer 2011;47:1006–12
   PubMed Web of Science ®Google Scholar
• Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): Inhibition of macrophage differentiation and cytokine production. Cancer Res 2005;65:2964–71
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70:2235–44
   PubMed Web of Science ®Google Scholar
• Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23:249–62
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689–98
   PubMed Web of Science ®Google Scholar
• Kampmann E, Harnicek D, Cardoso Martins AS, Eppink B, Gallmeier E, Lindner L, et al. Heat-shock (H-S) and trabectedin efficacy in human soft-tissue sarcoma (STS) cells in vitro. J Clin Oncol 2013;31. (suppl; abstr e13540)
   Web of Science ®Google Scholar
• Kampmann E, Harnicek D, Cardoso Martins SA, Tanovic A, Knösel T, Laubender R, et al. Trabectedin with regional hyperthermia. Experiences in patients with high-risk liposarcoma. Connective Tissue Oncology Society, 18th Annual Meeting 2013 (PO 355), New York
   Google Scholar